31 results about "Erythrocyte aggregation" patented technology

A method for optical measurements of desired parameters of the patient's blood is presented. A state of the blood flow cessation is provided within a measurement region and maintained during a predetermined time period. Measurement sessions are performed within this predetermined time period. Each measurement session includes at least two measurements with different wavelengths of incident light. Obtained measured data is representative of the time dependence of light response of the blood in the measurement region. The analyses of the measured data enables the determination of the desired blood parameters extracted from optical characteristics associated with the erythrocytes aggregation process during the state of the blood flow cessation.

The invention relates to a health care composite which consists of lecithin, grape pip extract and ginkgo leaf extract. The invention consists of the lecithin, the grape pip extract and the ginkgo leaf extract together; wherein, the lecithin accounts for 10 percent to 80 percent of the total weight, the grape pip extract accounts for 1-50 percent of the total weight and ginkgo leaf extract accounts for 1-50 percent of the total weight. The invention has the advantages that: the lecithin has the functions of nourishing the brain, improving intelligence, regulating blood lipid, eliminating fatigue, improving sleep, and so on; the grape pip extract has mighty antioxidation for the human body, can reduce erythrocyte aggregation and the permeability of capillary vessel; the ginkgo leaf extract can improve cerebrovascular circulation, protect brain cells from being damaged due to ischemia, dilate the coronary artery, prevent angina and myocardial infarction, eliminate harmful oxygen free radical, promote immunity and resist aging, and so on; the composite combined by three medicines brings convenience to consumers for oral administration and integrates three efficacies into a whole, thus enhancing the curative effect of the health care product.

A method and apparatus are presented for non-invasive determination of blood clotting related and blood circulation related parameters of a mammal. At least one stimulus ST is non-invasively induced in a blood containing medium in the mammal for a preset period of time tST. This at least one stimulus is selected to cause at least one of the following to occur: (a) inducing at least two of three Virchow's triad elements including abnormalities of blood flow; abnormalities of blood constituents and abnormalities of the blood vessel wall, and (b) inducing a change in red blood cell (RBC) aggregation or local blood viscosity. Measurements are non-invasively performed at a measurement location in the mammal by applying an external field thereto for a preset time period tm, a response of the measurement location to the applied field is detected, and measured data indicative thereof generated. At least a portion of the measured data and stimulus related data are processed so as to determine a relation between a time function of the at least one stimulus ST(t) and a time function of the measured data OR(t). This relation is indicative of at least one blood circulation and blood coagulation related parameter of the mammal.

A device and / or methodology are described that include a mechanism for separating erythrocytes from other constituents of blood and for purifying leukocytes from blood. The separation and purification aspects may be provided in separate components or within the same component. The separation aspect assists in separating erythrocytes (red blood cells) from other cells in blood, such as by aggregation of the red blood cells. A suitable aggregation device or device component uses chambers with at least one small dimension (e.g., a microfluidic chip) to control the interaction of the blood with a solution containing a high molecular weight polymer (e.g., dextran) to achieve separation.

The invention relates to a supported hemoglobin composition and a preparation method thereof. The preparation method comprises the following steps: (1) dissolving a carrier polyethylene glycol-poly(lactide-co-glycolide) into an organic solvent, mixing with a water solution of hemoglobin, and carrying out ultrasonic treatment to form primary emulsion; (2) adding a water solution of a surfactant to the primary emulsion obtained in the step (1), mixing and carrying out ultrasonic treatment to form a compound emulsion; and (3) removing the organic solvent, and centrifuging to obtain the supported hemoglobin composition. The supported hemoglobin composition is prepared by a double emulsion method; the method is simple and feasible; the prepared supported hemoglobin composition has oxygen carrying and releasing functions, has rheological characteristics similar to whole blood, is high in stability and good in blood compatibility, and does not cause erythrocyte aggregation; and the carrier material provided by the invention is prepared from abundant raw material, has the advantages of low cost, biocompatibility, biological affinity and no toxicity and is prone to be chemically modified.

The invention provides a high-efficiency hemostatic material based on chitosan fiber and a preparation method thereof. In the invention, the chitosan is firstly spun to obtain the chitosan fiber substrate, and then carboxyl and catechol structures are simultaneously grafted on the chitosan fiber substrate. The hemostatic material can quickly absorb water in the blood to swell, thereby significantly improving the hemostatic rate. The introduction of the carboxyl group makes it have super liquid absorption ability, so that the platelets in the blood at the bleeding site can quickly adhere and aggregate to form a thrombus, and the hydroxyl group on the catechol group can complex with the iron ions in the blood red blood cells, causing the red blood cells to aggregate It plays a role in stabilizing blood clots, and finally achieves the effect of rapid hemostasis. The high-efficiency hemostatic material provided by the invention is especially suitable for massive bleeding.

An inflammatory marker is calculated using a nonlinear function including, as variables, a parameter associated with an erythrocyte aggregation and another parameter associated with an erythrocyte density. The parameter associated with the erythrocyte aggregation is calculated based on a syllectogram measured from a blood specimen. The parameter associated with the erythrocyte density is measuredfrom the blood specimen.

The invention relates to a medicine for curing cerebral thrombosis and a preparation method thereof. The medicine of the invention is prepared by raw medicines with portions according to the followingweight ratio: 70-90 portions of Bupleurum chinense DC, 90-110 portions of RhizomaChuanxiong, 70-90 portions of root of red rooted salvia, 150-170 portions of radix astragali, 80-100 portions of earthworm, 50-70 portions of radix curcumae, 140-160 portions of core-removing hawthorn, 40-50 portions of radix notoginseng and 1.5-2.5 portions of borneol. The preparation method comprises that the radixnotoginseng are ground into 120 meshes of fine powder, the borneol is ground into 120 meshes of fine powder, and the Bupleurum chinense DC, the RhizomaChuanxiong, the root of red rooted salvia, the radix astragali, the earthworm, the radix curcumae and the core-removing hawthorn are cut into chips which are decocted with 1000g water for three times and each time is decocted for one hour; the rawmaterials being decocted are extracted, filtered, compressed, dried and ground into 120 meshes of fine powder, in which the radix notoginseng fine powder and the borneol fine powder are added and mixed evenly, thus obtaining the medicine through split charging into 0.5g of capsules. The medicine of the invention can promote blood circulation by removing blood stasis, warm channels and expel cold,restore consciousness and resuscitate and resist platelet aggregation; moreover, the medicine of the invention also can replenish qi to secure the exterior, clear away heat and toxic material, nourishblood and tranquilize mind and resist thrombosis; furthermore, the medicine of the invention can relieve the depressed liver, cool blood and remove stagnation and reduce erythrocyte aggregation; themedicine further can relieve muscles and warm channels, promote salivation and activate yang, dispel wind and toxicity, relieve heart and restlessness and regenerate tissues.

The present invention provides methods and compositions for separating cells from a sample containing erythrocytes. The method is for recovering desired cells from a sample containing the desired cells, erythrocytes and undesired cells comprising: a) contacting the sample with a composition, said composition comprising: i) an erythrocytes aggregation reagent ii) at least one antigen recognizing moiety coupled to a magnetic particle, wherein said particle with said at least one antigen recognizing moiety specifically binds to at least one antigen specific for one or more undesired cellular components; b) applying simultaneously i) gravity sedimentation for sedimentation of erythrocytes and ii) a magnetic field gradient to said sample for immobilizing said magnetic particle generating a pellet and a supernatant phase, and c) recovering the desired cells from the supernatant phase. Compositions for the use within the present method are also disclosed.

The invention discloses medical equipment for treatment of microcirculation diseases. The equipment includes a blood rheology detector, a resonance pool, magnetization coils and a control system. Ultrasonic wave of specific amplitude is transmitted to foot blood vessels through liquid to depolymerize erythrocyte rouleau flowing through the blood vessels, thus improving erythrocyte deformability, and also magnetization is carried out on venous blood flowing through legs, thus reaching the purpose of treating microcirculation diseases. The invention has the beneficial effects that: microcirculation disturbance is the source of all diseases, the therapeutic equipment for microcirculation diseases provided by the invention can break red blood cell aggregation in blood, improve red blood cell deformability, and reduce blood viscosity. The therapeutic equipment has the characteristics of fast and efficient use and low cost, thus providing treatment equipment for prevention and treatment of diseases caused by diabetes, high blood pressure, stroke, myocardial infarction and other microcirculations.

The invention discloses a method of analyzing a platelet aggregation function according to platelet size changes, and belongs to the field of clinical laboratory medicine. The method of analyzing the platelet aggregation function according to the platelet size changes measures the platelet size changes before after aggregation processing, and calculates the aggregation rate value of platelet according to the size changes of the platelet in a sample, and therefore the strength of the platelet aggregation function can be reflected. The method of analyzing the platelet aggregation function according to the platelet size changes also can be applied to erythrocyte aggregation rate analysis.